---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-137432"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-06-09T23:59:59+00:00"
generated_at: "2026-05-19T17:34:54.731096+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam reports positive AD biomarker data from BROADWAY; p-tau217 reduced in ITT and ApoE4 carriers

## Summary
- Statistically significant lower absolute change in p-tau217 over 12 months vs placebo in full ITT (p<0.002) and ApoE4 carriers (p=0.0215).
- AD sub-study included 1,727 patients, 367 ApoE4 carriers; primary measure was p-tau217 change.
- Company plans to present full results at AAIC conference in Toronto in July 2025.
- Results build on prior genetic, preclinical, and Phase 2a data supporting CETP inhibition for AD prevention.
- Obicetrapib is an oral CETP inhibitor primarily developed for LDL-C reduction; safety shown in large trials.

## SEC filing metadata
- accession: 0001193125-25-137432
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-06-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000119312525137432/0001193125-25-137432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000119312525137432/d74901d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-137432
- JSON: https://secwatch.observer/filing/0001193125-25-137432.json
- Plain text: https://secwatch.observer/filing/0001193125-25-137432.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.